Pegipanermin: meta-analysis of COVID-19 studies

All studies   Mortality   ICU   Hospitalization   RCTs   RCT mortality   All outcomes  
0 0.5 1 1.5+ All studies -290% 1 77 Improvement, Studies, Patients Relative Risk Mortality -290% 1 77 ICU admission -241% 1 77 Hospitalization -38% 1 77 RCTs -290% 1 77 Late -290% 1 77 Pegipanermin for COVID-19 c19early.org December 2025 Favorspegipanermin Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Tesi (DB RCT) -290% 3.90 [0.46-33.3] death 4/39 1/38 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Late treatment -290% 3.90 [0.46-33.3] 4/39 1/38 290% higher risk All studies -290% 3.90 [0.46-33.3] 4/39 1/38 290% higher risk 1 pegipanermin COVID-19 study c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Effect extraction pre-specified(most serious outcome) Favors pegipanermin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Tesi (DB RCT) -290% 3.90 [0.46-33.3] 4/39 1/38 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Late treatment -290% 3.90 [0.46-33.3] 4/39 1/38 290% higher risk All studies -290% 3.90 [0.46-33.3] 4/39 1/38 290% higher risk 1 pegipanermin COVID-19 mortality result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Favors pegipanermin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Tesi (DB RCT) -241% 3.41 [0.76-15.4] 7/39 2/38 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.11 Late treatment -241% 3.41 [0.76-15.4] 7/39 2/38 241% higher risk All studies -241% 3.41 [0.76-15.4] 7/39 2/38 241% higher risk 1 pegipanermin COVID-19 ICU result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.11 Favors pegipanermin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Tesi (DB RCT) -38% 1.38 [0.88-2.16] hosp. time 39 (n) 38 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.16 Late treatment -38% 1.38 [0.88-2.16] 39 (n) 38 (n) 38% higher risk All studies -38% 1.38 [0.88-2.16] 39 (n) 38 (n) 38% higher risk 1 pegipanermin COVID-19 hospitalization result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.16 Favors pegipanermin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Tesi (DB RCT) -290% 3.90 [0.46-33.3] death 4/39 1/38 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Late treatment -290% 3.90 [0.46-33.3] 4/39 1/38 290% higher risk All studies -290% 3.90 [0.46-33.3] 4/39 1/38 290% higher risk 1 pegipanermin COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Effect extraction pre-specified(most serious outcome) Favors pegipanermin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Tesi (DB RCT) -290% 3.90 [0.46-33.3] 4/39 1/38 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Late treatment -290% 3.90 [0.46-33.3] 4/39 1/38 290% higher risk All studies -290% 3.90 [0.46-33.3] 4/39 1/38 290% higher risk 1 pegipanermin COVID-19 RCT mortality result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Favors pegipanermin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Tesi (DB RCT) -290% 3.90 [0.46-33.3] death 4/39 1/38 Improvement, RR [CI] Treatment Control Tesi (DB RCT) -241% 3.41 [0.76-15.4] ICU 7/39 2/38 Tesi (DB RCT) -62% 1.62 [0.65-4.03] progression 10/39 6/38 Tesi (DB RCT) -38% 1.38 [0.88-2.16] hosp. time 39 (n) 38 (n) Pegipanermin COVID-19 outcomes c19early.org December 2025 Favors pegipanermin Favors control